Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, IDEAYA Biosciences, Inc. (IDYA) has a Wall Street consensus price target of $44.25, based on estimates from 24 covering analysts. With the stock currently trading at $32.20, this represents a potential upside of +37.4%. The company has a market capitalization of $2.83B.
Analyst price targets range from a low of $30.00 to a high of $60.00, representing a 68% spread in expectations. The median target of $43.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IDYA trades at a trailing P/E of -25.2x. Analysts expect EPS to grow -207.1% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how IDYA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for IDYA is $44.25, representing 37.4% upside from the current price of $32.2. With 24 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IDYA has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $44.25 implies 37.4% upside from current levels.
IDYA's current price is $32.2 with a consensus target of $44.25 (37.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $60 for IDYA, while the most conservative target is $30. The consensus of $44.25 represents the median expectation. These targets typically reflect 12-month expectations.
IDYA is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IDYA stock forecast based on 24 Wall Street analysts shows a consensus price target of $44.25, with estimates ranging from $30 (bear case) to $60 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IDYA, with a "Buy" consensus rating and $44.25 price target (37.4% upside). 22 of 24 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IDYA analyst price targets range from $30 to $60, a 68% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.25 consensus represents the middle ground.